CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-4797PMID 18698043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper
• Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

  2007cited by this paper
• Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

  2007cited by this paper
• Future directions in tumor immunotherapy: CTLA4 blockade

  2007cited by this paper
• Immune surveillance of tumors.

  2007cited by this paper
• Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

  2007cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines1

  2006cited by this paper
• Human T cell responses against melanoma.

  2006cited by this paper
• Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.

  2006cited by this paper
• Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”

  2006cited by this paper
• Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

  2006cited by this paper
• CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

  2006cited by this paper
• Effector memory T cells, early metastasis, and survival in colorectal cancer.

  2005cited by this paper
• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  2005cited by this paper
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential

  2005cited by this paper
• CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

  2004cited by this paper
• Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  2003cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

  2001cited by this paper
• CTLA-4 regulates induction of anergy in vivo.

  2001cited by this paper
• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

  2001cited by this paper
• Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4

  2000cited by this paper
• Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

  2000cited by this paper
• Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells.

  2000cited by this paper
• B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

  2000cited by this paper
• CTLA-4-Mediated inhibition of early events of T cell proliferation.

  1999cited by this paper
• Secondary but not primary T cell responses are enhanced in CTLA‐4‐deficient CD8+ T cells

  1998cited by this paper
• Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.

  1997cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

  1995cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper
• Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

  1988cited by this paper

• Boosting immunotherapy efficacy: Empowering the Potency of Dendritic cells loaded with breast cancer lysates through CTLA-4 suppression

  2024cites this paper
• Immune checkpoint inhibitors in metastatic melanoma therapy (Review)

  2024cites this paper
• Prognostic value of a novel myeloid-to-lymphoid ratio biomarker in advanced gastric cancer

  2024cites this paper
• Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview

  2023cites this paper
• Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma

  2022cites this paper
• Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

  2022cites this paper
• Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome

  2022cites this paper
• Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

  2021cites this paper
• Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis

  2021cites this paper
• Research trends and public interests of immune checkpoint blockade in melanoma: a visualization and bibliometric analysis (Preprint)

  2021cites this paper
• Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.

  2021cites this paper
• Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)

  2020cites this paper
• Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

  2019cites this paper
• Rational combination immunotherapeutic approaches for effective cancer treatment.

  2019cites this paper
• Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review

  2019cites this paper
• Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.

  2019cites this paper
• Treg-mediated acquired resistance to immune checkpoint inhibitors.

  2019cites this paper
• T-Cell Lymphopenia in Patients with Advanced Thyroid Carcinoma Is Associated with Poor Prognosis.

  2019cites this paper
• CTLA-4: a moving target in immunotherapy.

  2018cites this paper
• Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

  2018cites this paper
• Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges

  2018cites this paper
• Inflammation: A key process in skin tumorigenesis

  2018cites this paper
• Strategies to Reduce Intratumoral Regulatory T Cells

  2018cites this paper
• Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting

  2018cites this paper
• Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure

  2017cites this paper
• Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity

  2017cites this paper
• Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

  2017cites this paper
• Contrasting effects of cyclophosphamide on anti‐CTL‐associated protein 4 blockade therapy in two mouse tumor models

  2017cites this paper
• Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer

  2016cites this paper
• Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab

  2016cites this paper
• Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

  2016cites this paper
• Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors

  2016cites this paper
• Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma

  2016cites this paper
• Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

  2016cites this paper
• Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.

  2015cites this paper
• Regulatory T cells in the immunotherapy of melanoma

  2015cites this paper
• Inflammation markers in cutaneous melanoma - edgy biomarkers for prognosis

  2015cites this paper
• Immunologic correlates in the course of treatment with immunomodulating antibodies.

  2015cites this paper
• Future prospects for the immunotherapy of premalignant uVIN lesions

  2015cites this paper
• Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer

  2014cites this paper
• Cutaneous melanoma.

  2014cites this paper
• Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.

  2014cites this paper
• Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

  2014cites this paper
• Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients.

  2014cites this paper
• Intratumoral checkpoint subversion as a strategy for minimizing adverse effects

  2014cites this paper
• Cancer Vaccines

  2014cites this paper
• Procédés de prédiction de la réponse anti-ctla-2 et de la rechute d'un cancer

  2014cites this paper
• Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

  2014cites this paper
• Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state

  2014cites this paper
• Revisiting Immune-Based Therapies for Aggressive Follicular Cell–Derived Thyroid Cancers

  2013cites this paper
• Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th 2 and Regulatory Immunity through OX 40 L and ICOSL

  2013cites this paper
• Immune co-signaling to treat cancer

  2013cites this paper
• CD4 lymphopenia to identify end-of-life metastatic cancer patients.

  2013cites this paper
• Tremelimumab: a review of development to date in solid tumors.

  2013cites this paper
• Immune correlates of melanoma survival in adoptive cell therapy

  2013cites this paper
• Therapeutic Targeting Regulatory T Cells in Tumor

  2013cites this paper
• Association between CTLA-4 60G/A and -1661A/G Polymorphisms and the Risk of Cancers: A Meta-Analysis

  2013cites this paper
• Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL

  2013cites this paper
• Update on the role of ipilimumab in melanoma and first data on new combination therapies

  2013cites this paper
• ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.

  2012cites this paper
• Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of Northeast China

  2012cites this paper
• T-regulatory cells: key players in tumor immune escape and angiogenesis.

  2012cites this paper
• The immune system--a hidden treasure for biomarker discovery in cutaneous melanoma.

  2012cites this paper
• Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

  2012cites this paper
• Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma

  2012cites this paper
• Influence of human immune cells on cancer: studies at the University of Colorado

  2012cites this paper
• Current Approaches to Identify and Evaluate Cancer Biomarkers for Patient Stratification

  2012cites this paper
• Melanoma & biomarkers of immunoresponsiveness

  2012cites this paper
• Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-&agr; or TLR-9 Agonist and GM-CSF With Peptide Vaccination

  2012cites this paper
• Ipilimumab (Yervoy) and the TGN1412 catastrophe.

  2012cites this paper
• Immune-Therapy in Cutaneous Melanoma – Efficacy Immune Markers

  2012cites this paper
• The tumour microenvironment influences antigen specific T cell transmigration

  2012cites this paper
• T Regulatory Cells and Cancer Immunotherapy

  2011cites this paper
• CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans

  2011cites this paper
• [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].

  2011cites this paper
• Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma

  2011cites this paper
• Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.

  2011cites this paper
• A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

  2011cites this paper
• Overcoming Melanoma Immune Tolerance: Non-specific CTLA-4 Blockade/Interferon-alfa and Antigen Specific Immunization with TLR-9 Stimulation/Local GM-CSF as Components of a Melanoma Immunotherapeutic Strategy and Associated Biomarkers of Therapeutic Benefit

  2011cites this paper
• Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

  2011cites this paper
• Modulation of T regulatory activity for cancer therapy

  2011cites this paper
• Anticorps anti-CTLA-4 : Une avancée thérapeutique majeure dans le traitement du mélanome métastatique

  2011cites this paper
• [Immunotherapy of cancer: light at the end of the tunnel?].

  2011cites this paper
• Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach.

  2011cites this paper
• Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low‐dose IL‐2

  2011cites this paper
• Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

  2011cites this paper
• Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond.

  2011cites this paper
• Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

  2010influential citation
• Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.

  2010cites this paper
• Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile.

  2010cites this paper
• Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors

  2010cites this paper
• Clinical development of the anti-CTLA-4 antibody tremelimumab.

  2010cites this paper
• Immunotherapy for Melanoma: Current Status and Perspectives

  2010cites this paper
• Regulatory T Cell as a Target for Cancer Therapy

  2010cites this paper
• T regulatory cells, the evolution of targeted immunotherapy.

  2010cites this paper
• CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy.

  2010cites this paper
• Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma

  2010cites this paper
• Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.

  2010cites this paper
• Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma

  2009cites this paper
• CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

  2009cites this paper